SK288131B6 - CTLA4 mutant molecule or nucleic acid molecule, vector and host vector system, host cell, CTLA4 mutant protein, method for producing and use thereof, pharmaceutical composition and regulation method - Google Patents

CTLA4 mutant molecule or nucleic acid molecule, vector and host vector system, host cell, CTLA4 mutant protein, method for producing and use thereof, pharmaceutical composition and regulation method Download PDF

Info

Publication number
SK288131B6
SK288131B6 SK1570-2002A SK15702002A SK288131B6 SK 288131 B6 SK288131 B6 SK 288131B6 SK 15702002 A SK15702002 A SK 15702002A SK 288131 B6 SK288131 B6 SK 288131B6
Authority
SK
Slovakia
Prior art keywords
ctla4
ctla4 mutant
molecule
mutant molecule
cell
Prior art date
Application number
SK1570-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK15702002A3 (sk
Inventor
Robert J. Peach
Joseph R. Naemura
Peter S. Linsley
Jurgen Bajorath
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SK15702002A3 publication Critical patent/SK15702002A3/sk
Publication of SK288131B6 publication Critical patent/SK288131B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1570-2002A 2000-05-26 2001-05-23 CTLA4 mutant molecule or nucleic acid molecule, vector and host vector system, host cell, CTLA4 mutant protein, method for producing and use thereof, pharmaceutical composition and regulation method SK288131B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (2)

Publication Number Publication Date
SK15702002A3 SK15702002A3 (sk) 2004-01-08
SK288131B6 true SK288131B6 (sk) 2013-10-02

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1570-2002A SK288131B6 (sk) 2000-05-26 2001-05-23 CTLA4 mutant molecule or nucleic acid molecule, vector and host vector system, host cell, CTLA4 mutant protein, method for producing and use thereof, pharmaceutical composition and regulation method

Country Status (41)

Country Link
EP (3) EP1248802B9 (da)
JP (1) JP4328525B2 (da)
KR (2) KR100889887B1 (da)
CN (2) CN1309735C (da)
AR (1) AR031699A1 (da)
AT (1) ATE271066T1 (da)
AU (2) AU6346601A (da)
BE (1) BE2011C041I2 (da)
BR (1) BRPI0111191B8 (da)
CA (1) CA2409748C (da)
CY (2) CY2011019I1 (da)
CZ (1) CZ304451B6 (da)
DE (2) DE60104282T2 (da)
DK (1) DK1248802T3 (da)
EC (1) ECSP024365A (da)
EE (2) EE05557B1 (da)
EG (1) EG24459A (da)
ES (2) ES2225549T3 (da)
FR (1) FR11C0053I2 (da)
GE (1) GEP20053658B (da)
HK (2) HK1048126B (da)
HU (2) HU228137B1 (da)
IL (1) IL152315A (da)
LT (1) LT5133B (da)
LU (1) LU91902I2 (da)
LV (1) LV12994B (da)
MX (1) MXPA02011534A (da)
MY (1) MY136113A (da)
NO (2) NO330797B1 (da)
PE (1) PE20011338A1 (da)
PL (1) PL206267B1 (da)
PT (1) PT1248802E (da)
RU (1) RU2283847C2 (da)
SI (1) SI1248802T1 (da)
SK (1) SK288131B6 (da)
TR (1) TR200402703T4 (da)
TW (2) TWI314933B (da)
UA (1) UA87432C2 (da)
UY (1) UY26723A1 (da)
WO (1) WO2001092337A2 (da)
ZA (1) ZA200208944B (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
HU227669B1 (en) * 2000-07-03 2011-11-28 Bristol Myers Squibb Co Use of soluble ctla4 mutants
ATE390931T1 (de) 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
WO2003088991A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
PL377603A1 (pl) * 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Poprawa jakości produktu w hodowlach komórek ssaczych do wytwarzania białka
WO2004058800A2 (en) 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
EP1684791A4 (en) 2003-10-27 2009-07-01 Amgen Inc COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
KR101391457B1 (ko) * 2005-12-20 2014-05-19 브리스톨-마이어스 스큅 컴퍼니 조성물 및 조성물의 제조 방법
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
EP2121756A4 (en) 2006-12-20 2011-08-31 Mmrglobal Inc ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE
KR101383476B1 (ko) * 2007-11-01 2014-04-11 아스테라스 세이야쿠 가부시키가이샤 면역억제 폴리펩티드 및 핵산
PT2344540T (pt) * 2008-10-02 2018-02-02 Aptevo Res & Development Llc Proteínas de ligação multi-alvo antagonistas de cd86
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2011113019A2 (en) * 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Ctla4 proteins and their uses
WO2012115874A1 (en) 2011-02-23 2012-08-30 Amgen Inc. Cell culture media for uvc exposure and methods related thereto
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
WO2013148049A1 (en) * 2012-03-29 2013-10-03 The General Hospital Corporation Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
SG10201609447XA (en) * 2012-05-11 2017-01-27 Medimmune Llc Ctla-4 variants
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
WO2014004857A1 (en) 2012-06-27 2014-01-03 Orban Biotech Llc Ctla4 fusion proteins for the treatment of diabetes
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
CN106029896B (zh) 2014-01-13 2020-10-27 美国安进公司 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
SG10202113019XA (en) 2014-06-04 2021-12-30 Amgen Inc Methods for harvesting mammalian cell cultures
BR112017011652A2 (pt) 2014-12-01 2018-06-26 Amgen Inc. processo para manipulação do nível de teor de glicano de uma glicoproteína
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
DK3283508T3 (en) 2015-04-17 2021-05-31 Alpine Immune Sciences Inc Immunomodulatory Proteins with Tunable Affinities
EP3702470A3 (en) 2015-09-09 2020-10-07 The Trustees of Columbia University in the City of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
KR20180073693A (ko) 2015-11-09 2018-07-02 브리스톨-마이어스 스큅 컴퍼니 Cho 세포에서 생산되는 폴리펩티드의 품질 속성을 조작하는 방법
CN109715210B (zh) * 2016-09-19 2023-05-30 昂科医药 Cd80和cd86结合蛋白组合物及其用途
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
WO2018195402A1 (en) 2017-04-20 2018-10-25 Egenesis, Inc. Methods for generating genetically modified animals
EP4442268A2 (en) 2017-10-10 2024-10-09 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
WO2021038296A2 (en) 2019-08-27 2021-03-04 Tonix Pharma Holdings Limited Modified tff2 polypeptides
JP2022550930A (ja) 2019-12-06 2022-12-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｖｅｇｆタンパク質組成物及びその製造方法
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
AU2021293591A1 (en) 2020-06-18 2023-01-19 Regeneron Pharmaceuticals, Inc. Heavy peptide approach to accurately measure unprocessed C-terminal lysine
US20230287322A1 (en) 2020-07-28 2023-09-14 Seagen Inc. Methods and systems for producing polypeptides
KR20240125949A (ko) 2021-12-16 2024-08-20 브리스톨-마이어스 스큅 컴퍼니 바이러스 불활성화를 위한 세제
WO2023167847A2 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Bioreactor for antibody production

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
EP0606217B2 (en) * 1991-06-27 2008-12-03 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
CA2346496A1 (en) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
HU227669B1 (en) * 2000-07-03 2011-11-28 Bristol Myers Squibb Co Use of soluble ctla4 mutants

Also Published As

Publication number Publication date
NO330797B1 (no) 2011-07-18
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
DE60104282T2 (de) 2005-10-13
CY1117625T1 (el) 2017-04-26
DE60104282D1 (de) 2004-08-19
IL152315A0 (en) 2003-05-29
KR100895134B1 (ko) 2009-05-04
ECSP024365A (es) 2003-03-31
NO20025656D0 (no) 2002-11-25
HUP0302201A2 (hu) 2003-10-28
JP4328525B2 (ja) 2009-09-09
ES2225549T3 (es) 2005-03-16
AR031699A1 (es) 2003-10-01
CA2409748C (en) 2008-09-16
MXPA02011534A (es) 2004-08-12
EE200200659A (et) 2004-06-15
ATE271066T1 (de) 2004-07-15
GEP20053658B (en) 2005-11-10
NO2011027I2 (da) 2011-12-15
PL366231A1 (en) 2005-01-24
WO2001092337A3 (en) 2002-05-10
FR11C0053I1 (da) 2012-01-13
EP1248802B1 (en) 2004-07-14
EP1248802B9 (en) 2005-05-11
TWI319405B (en) 2010-01-11
MY136113A (en) 2008-08-29
PL206267B1 (pl) 2010-07-30
NO2011027I1 (no) 2012-01-09
EP3029062A1 (en) 2016-06-08
PT1248802E (pt) 2004-11-30
BE2011C041I2 (da) 2020-08-20
LT2002114A (en) 2003-12-29
CZ304451B6 (cs) 2014-05-14
CA2409748A1 (en) 2001-12-06
UA87432C2 (uk) 2009-07-27
EE05557B1 (et) 2012-08-15
LV12994B (en) 2003-08-20
HU228137B1 (en) 2012-12-28
SI1248802T1 (en) 2005-02-28
CZ20023892A3 (cs) 2003-09-17
BRPI0111191B1 (pt) 2019-12-31
UY26723A1 (es) 2001-12-28
FR11C0053I2 (fr) 2013-01-11
NO20025656L (no) 2002-11-25
HK1071931A1 (zh) 2005-08-05
BR0111191A (pt) 2004-07-06
WO2001092337A2 (en) 2001-12-06
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
LT5133B (lt) 2004-05-25
EP1536234A2 (en) 2005-06-01
EE05458B1 (et) 2011-08-15
BRPI0111191B8 (pt) 2021-05-25
AU2001263466C1 (en) 2006-10-26
KR100889887B1 (ko) 2009-03-24
DK1248802T3 (da) 2004-11-15
CN101255192A (zh) 2008-09-03
HUP0302201A3 (en) 2010-01-28
IL152315A (en) 2010-04-15
CN1309735C (zh) 2007-04-11
CN1441810A (zh) 2003-09-10
ES2571852T3 (es) 2016-05-27
SK15702002A3 (sk) 2004-01-08
HK1048126B (zh) 2005-03-04
HK1048126A1 (en) 2003-03-21
CY2011019I1 (el) 2016-12-14
EE201100050A (et) 2011-10-17
AU6346601A (en) 2001-12-11
EP1536234B1 (en) 2016-03-16
EG24459A (en) 2009-07-16
TWI314933B (en) 2009-09-21
EP1536234A3 (en) 2009-06-03
JP2004511213A (ja) 2004-04-15
TR200402703T4 (tr) 2004-11-22
TW200906857A (en) 2009-02-16
ZA200208944B (en) 2004-02-13
AU2001263466B2 (en) 2006-04-27
DE122011100063I1 (de) 2012-06-14
RU2283847C2 (ru) 2006-09-20
HUS1300012I1 (hu) 2016-08-29
KR20030009502A (ko) 2003-01-29
PE20011338A1 (es) 2002-01-13

Similar Documents

Publication Publication Date Title
US20210115107A1 (en) Methods of treatment using ctla4 molecules
JP4328525B2 (ja) 可溶性ｃｔｌａ４突然変異体分子およびその用途
DK1935427T3 (da) Anvendelser af opløselige, mutante ctla4-molekyler
AU2006203199B2 (en) Soluble CTLA4 mutant molecules and uses thereof
DK1536234T3 (da) Opløselige mutante ctla4-molekyler og anvendelser deraf
NZ542231A (en) Soluble CTLA4 mutant fusion molecules and uses thereof
BG107210A (bg) Разтворими ctla4 мутантни молекули и тяхното използване

Legal Events

Date Code Title Description
SPCF Filing of an spc

Free format text: PRODUCT NAME: BELATACEPT; REGISTRATION NO/DATE: EU/1/11/694/001 - EU/1/11/694/002 20110617

Spc suppl protection certif: 5004-2014

Filing date: 20140210

SPCG Grant of an spc

Free format text: PRODUCT NAME: BELATACEPT; REGISTRATION NO/DATE: EU/1/11/694/001 - EU/1/11/694/002 20110617

Spc suppl protection certif: 152 5004-2014

Filing date: 20140210

Extension date: 20260524

MK4A Patent expired

Expiry date: 20210523